血管加压素治疗脓毒性休克:随机对照试验的个体患者数据荟萃分析
该个体患者数据荟萃分析纳入4项随机对照试验共1453例成人脓毒性休克患者,比较血管加压素与任何其他血管活性药物。主要终点28天死亡率无差异(RR 0.98,95%CI 0.86-1.12),严重不良事件无差异(RR 1.02,95%CI 0.82-1.26)。血管加压素增加数字缺血(ARD 1.7%,95%CI 0.3%-3.2%)但减少心律失常(ARD -2.8%,95%CI -0.2%至-5.3%),并减少肾脏替代治疗需求(RR 0.86,95%CI 0.74-0.99),但该发现对敏感性分析不稳健。预设亚组无显著交互作用。
要点
- 在1453例成人脓毒性休克患者中,血管加压素对28天死亡率无影响(RR 0.98,95%CI 0.86-1.12)。
- 血管加压素增加数字缺血风险(ARD 1.7%,95%CI 0.3%-3.2%),但减少心律失常(ARD -2.8%,95%CI -0.2%至-5.3%)。
- 血管加压素减少肾脏替代治疗需求(RR 0.86,95%CI 0.74-0.99),但该发现对敏感性分析不稳健。
- 严重不良事件(RR 1.02,95%CI 0.82-1.26)、肠系膜缺血和急性冠脉综合征事件两组相似。
- 预设亚组(基线肾损伤严重程度、基线乳酸、基线去甲肾上腺素需求、入组时间)无统计学显著交互作用。
适用人群与场景
- 成人脓毒性休克患者,来自4项随机对照试验,共1453例。
研究设计与关键结果
- 研究类型:个体患者数据荟萃分析,纳入截至2019年1月的随机对照试验,比较血管加压素与任何其他血管活性药物。
- 样本量:4项试验,共1453例患者。
- 主要终点:28天死亡率无影响(RR 0.98,95%CI 0.86-1.12);严重不良事件无差异(RR 1.02,95%CI 0.82-1.26)。
- 不良事件:血管加压素增加数字缺血(ARD 1.7%,95%CI 0.3%-3.2%),减少心律失常(ARD -2.8%,95%CI -0.2%至-5.3%);肠系膜缺血和急性冠脉综合征事件两组相似。
- 次要终点:血管加压素减少肾脏替代治疗需求(RR 0.86,95%CI 0.74-0.99),但该发现对敏感性分析不稳健。
- 亚组分析:预设亚组(基线肾损伤严重程度、基线乳酸、基线去甲肾上腺素需求、入组时间)无统计学显著交互作用。
证据类型、等级与局限
- 证据类型:个体患者数据荟萃分析(基于随机对照试验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血管加压素治疗脓毒性休克对28天死亡率无影响,置信区间宽。
- 作者认为血管加压素似乎安全,但副作用特征与去甲肾上腺素不同。
- 作者认为减少肾脏替代治疗需求的发现应谨慎解读。
- 作者建议未来试验应关注选定患者组的长期结局,并纳入关于可能减少肾脏替代治疗使用的成本效益分析。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We performed an individual patient data meta-analysis to investigate the possible benefits and harms of vasopressin therapy in adults with septic shock both overall and in pre-defined subgroups.
METHODS: Our pre-specified study protocol is published on PROSPERO, CRD42017071698. We identified randomised clinical trials up to January 2019 investigating vasopressin therapy versus any other vasoactive comparator in adults with septic shock. Individual patient data from each trial were compiled. Conventional two-stage meta-analyses were performed as well as one-stage regression models with single treatment covariate interactions for subgroup analyses.
RESULTS: Four trials were included with a total of 1453 patients. For the primary outcomes, there was no effect of vasopressin on 28-day mortality [relative risk (RR) 0.98, 95% CI 0.86-1.12] or serious adverse events (RR 1.02, 95% CI 0.82-1.26). Vasopressin led to more digital ischaemia [absolute risk difference (ARD) 1.7%, 95% CI 0.3%-3.2%] but fewer arrhythmias (ARD - 2.8%, 95% CI - 0.2% to - 5.3%). Mesenteric ischaemia and acute coronary syndrome events were similar between groups. Vasopressin reduced the requirement for renal replacement therapy (RRT) (RR 0.86, 95% CI 0.74-0.99), but this finding was not robust to sensitivity analyses. There were no statistically significant interactions in the pre-defined subgroups (baseline kidney injury severity, baseline lactate, baseline norepinephrine requirement and time to study inclusion).
CONCLUSIONS: Vasopressin therapy in septic shock had no effect on 28-day mortality although the confidence intervals are wide. It appears safe but with a different side effect profile from norepinephrine. The finding on reduced RRT should be interpreted cautiously. Future trials should focus on long-term outcomes in select patient groups as well as incorporating cost effectiveness analyses regarding possible reduced RRT use.
参考来源
- Nagendran M, Russell JA, Walley KR, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med. 2019. PMID: 31062052. doi:10.1007/s00134-019-05620-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。